Acetaminophen (APAP) overdose is a leading cause of untreatable liver failure. In the mouse 38 model of APAP-induced liver injury (AILI), the administration of recombinant human 39 interleukin 11 (rhIL11) is protective. Here we show that the beneficial effect of rhIL11 in the 40 mouse is due to its unexpected and paradoxical inhibition of endogenous mouse IL11 activity. 41 Contrary to the accepted paradigm IL11 is a potent hepatotoxin across species, which is secreted 42 from damaged hepatocytes to drive an autocrine loop of NOX4 and JNK-dependent apoptosis.
). Three weeks after 188 transgene induction, Il11-Tg mice had grossly abnormal and smaller (38%, P<0.0001) livers with 189 elevated serum ALT and AST levels, while other organs were unaffected ( Fig. 3B-D Fig. 5 A-B) . Histologically, there was marked portal vein dilatation and blood 191 accumulation in the sinusoids -suggestive of a sinusoidal obstruction syndrome -as well as 192 infiltrates around the portal triad ( Fig. 3E, Extended Data Fig. 5C ). Molecular analyses of Tg livers revealed activation of ERK, JNK, and CASP3 cleavage along with increased pro-194 inflammatory gene expression ( Fig. 3F, Extended Data Fig. 5D-E) . Thus secretion of IL11 195 from hepatocytes, as seen with APAP toxicity (Fig. 1) , is hepatotoxic. 196 197 IL11 stimulates NOX4-mediated reactive oxygen species production 198 IL11 signaling is required for APAP-driven JNK activation in vitro ( Fig. 1I-J) , which is known 199 to follow ROS production and GSH depletion. We examined liver GSH levels in Il11-Tg mice 200 and found they were diminished (62%, P<0.0001), indicating that IL11 signaling -directly or 201 indirectly -induces ROS (Fig. 3G ).
202
In fibroblasts, the expression of NOX4, an NADPH oxidase, and source of ROS, is 203 strongly associated with IL11 expression 15,25 , and hepatocyte-specific Nox4 deletion prevents 204 pathological activation of JNK 26 . Therefore, we investigated the relationship between IL11, 205 NOX4, and ROS in greater detail. In Il11-Tg mice, hepatic Nox4 expression was upregulated 206 (Fig 3H) . In primary human hepatocytes, IL11 stimulated dose-dependent GSH depletion over a 207 time course that mirrored ERK and JNK activation and was accompanied by NOX4 upregulation 208 ( Fig. 1G, Fig. 3I-K) . As expected, only species-specific IL11 induced NOX4 upregulation and 209 lowered GSH levels ( Fig. 3L, Extended Data Fig. 6A-D) . 210 APAP stimulation also resulted in NOX4 upregulation in hepatocytes, coincident with 211 depletion in hepatocyte GSH levels, which was blocked with the anti-IL11RA antibody X209 212 ( Fig. 3 M-N) . We reconsidered the effect of rhIL11 in inhibiting endogenous IL11-induced cell Fig. 8A-B) . The specificity of pharmacological inhibition of NOX4 was confirmed using 219 siRNA, which prevented IL11-induced hepatotoxicity ( Fig. 3P-Q, Extended Data Fig. 9A-B) . 220 Together these data show that IL11-stimulated NOX4 activity, which could also impact 221 mitochondrial ROS, is important for GSH depletion in the context of AILI. CKOs were administered APAP (400 mg kg -1 ) (Fig. 4A ). The day after APAP administration, 250 gross anatomy revealed small and discolored livers in control mice, whereas livers from CKO 251 mice looked normal (Fig. 4B) . Histology showed typical and extensive centrilobular necrosis in 252 control mice, which was not observed in CKOs (Fig. 4C) . 253 It was striking that CKO mice had 99% and 95% lower ALT and AST levels, 254 respectively, as compared to controls and GSH levels that were similar to baseline. Both groups 255 had similar levels of APAP and APAP-Glutathione (APAP metabolite) in the serum and thus 256 Il11ra1 deletion does not impact APAP metabolism ( Fig. 4D-F, Extended Data Fig. 10A-B) . 257 ERK and JNK activation was observed in control mice, but not in the CKOs (Fig. 4G) . Deletion 258 of the receptor in hepatocytes also significantly reduced inflammatory markers, suggesting that 259 inflammation in AILI is secondary to parenchymal injury. (Fig 4H) . Taken together, these data 278 We next tested if therapeutic inhibition of IL11 signaling was effective in mitigating AILI by 279 administering anti-Il11RA (X209) antibody 14 . Initially, we performed a preventive treatment by 280 injecting X209 or control antibody (10 mg kg -1 ) 16h prior to APAP. This approach reduced 281 serum markers of liver damage by over 70%, largely restored hepatic GSH levels, and limited 282 histological evidence of centrilobular necrosis (Fig. 5A-D, Extended Data Fig. 11A) . 283 Next, we administered anti-IL11RA therapy in a therapeutically-relevant mode by giving 284 antibody 3h after APAP, a time point by which APAP metabolism and toxicity is established and 285 after which most interventions have no effect in the mouse model of AILI (Fig. 5E) 9 . X209, 286 across a range of doses (2.5-10 mg kg -1 ), inhibited AILI with dose-dependent improvements in 287 markers of liver damage and in hepatic GSH levels. Reduced JNK and ERK activation 288 confirmed dose-dependent target coverage ( Fig. 5F-H, Extended Data Fig. 11B) . 289 Lastly, we determined whether inhibiting IL11 signaling had added value when given in 290 combination with the current standard of care, NAC, 3h after APAP dosing (Fig. 5I) . 291 Administration of NAC alone reduced serum levels of ALT and AST. However, NAC in 292 combination with X209 was even more effective than either NAC or X209 alone (ALT 293 reduction: NAC, 38%, P=0.0007; X209, 47%, P<0.0001; NAC+X209, 75%; P<0.0001) ( Fig. 5F,   294 J, Extended Data Fig. 11C) . At the molecular level, the degree of ERK and JNK inhibition with 295 NAC or NAC together with X209 mirrored the magnitude of ALT reduction in the serum and the 296 restoration of hepatic GSH levels (Fig. 5K-L) . As such, anti-IL11RA therapy has added benefits 297 when given in combination with the current standard of care. Liver regeneration with anti-IL11RA therapy 317 For patients presenting to the emergency room 8h or later after APAP OD there is no effective 318 treatment. This prompted us to test anti-IL11RA 10h after APAP (400 mg kg -1 ) administration to 319 mice (Fig. 6A) . Given the accelerated metabolism of APAP in the mouse, therapy at 10h in this 320 model is equivalent to the treatment of a human up to 24h post-APAP OD. We quantified APAP 321 and APAP-Glutathione in serum by mass spectrometry and found levels to be elevated compared 322 to saline-treated controls and equivalent between experimental groups, as expected (Extended 323 Data Fig. 12A-B) . Analysis of gross anatomy, histology and serum IL11, ALT and AST levels 324 revealed that X209 largely reversed liver damage by the second day after APAP, whereas IgG 325 treated mice had profound and sustained liver injury ( Fig. 6B-E, Extended Data Fig. 13A) . The 326 therapeutic antibody effectively blocked ERK and JNK activation throughout the course of the 327 experiment and this preceded a reduction in cleaved CASP3 at 24h (Fig. 6F, Extended Data 328 Fig. 13B) . 329 Interventions promoting liver regeneration, which has very large potential, may provide a 330 new means of treating AILI 12 . We therefore assessed the status of genes important for liver 331 regeneration 10 . Inhibition of IL11 signaling was associated with a robust signature of 332 regeneration with strong upregulation of PCNA, Cyclin D1/D3/E1, and phosphorylation of RB, 333 as seen during regeneration following partial hepatectomy 10 . EdU injection and histological 334 analyses showed very large numbers of nuclei with evidence of recent DNA synthesis in X209-335 treated mice as compared to controls (Fig. 6G) . We reassessed the effects X209 given 3h post-336 APAP (Fig. 5I-L) to see if regeneration was also associated with inhibition of IL11 signaling at 337 earlier time points. This proved to be the case, and the combination of X209 and NAC was more 338 effective than NAC alone in increasing molecular markers of regeneration, notably for Cyclin D1 339 and D3 (Fig. 6H) . 340 Finally, we administered X209 (20 mg kg -1 ) 10h after a higher and lethal acetaminophen 341 dose (550 mg kg -1 ) at a time point when mice were moribund and livers undergoing fulminant 342 necroinflammation (Fig. 6I) . X209-treated mice recovered and had a 90% survival by the study 343 end. In contrast, IgG-treated mice did not recover and succumbed with a 100% mortality within 344 48h, (Fig. 6J) . On day 8 after the lethal dose of APAP, X209-treated mice appeared healthy with 345 normal liver morphology and ALT levels were comparable to controls that had not received 346 APAP (Fig. 6K, Extended Data Fig. 14A-B ). Fig. 5D , the values of saline are the same as those used in S11A). (C) Serum AST 596 levels in mice treated with NAC (500 mg kg -1 ) alone or in combination with X209 (5 mg kg -1 ) 3h 597 after APAP injury (Schematic Fig. 5G) . independently of APAP and its metabolites. If the IL11 pathway is blocked either genetically or 626 therapeutically, hepatocyte cell death can be prevented and liver regeneration is restored.
Effects of anti-IL11RA administration early during APAP-induced liver injury
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